Objective To analyze a case of immune-related hepatitis induced by the combination treatment of disitamab vedotin and cadonilimab,in order to provide references for the safe and rational clinical use of these drugs.Methods The clinical pharmacists analyzed the clinical manifestations,diagnostic and therapeutic approach,and treatment outcomes of a patient with advanced bladder cancer who developed immune-related hepatitis following treatment with disitamab vedotin and cadonilimab.Results After treatment with glucocorticoid,the patient's aminotransferase and bilirubin levels recovered,and the immune-related hepatitis grade dropped below grade 1.Conclusion The clinical manifestations of immune-related hepatitis are atypical,and it may be life-threatening if not treated in time.Physicians should promptly identify immune-relat-ed hepatitis based on clinical symptoms and relevant tests to implement early intervention and prevent severe adverse reac-tions.
国家科技期刊平台
NSTL
万方数据
